Key result
Systemic thrombolysis benefits hemodynamically unstable acute PE, but bleeding risks outweigh benefits in normotensive patients.
Why the study?
High-risk pulmonary embolism is a time-critical condition in which acute right ventricular failure can rapidly progress to shock and cardiac arrest, requiring clear guidance on how contemporary risk stratification and bleeding risk should direct systemic thrombolysis and reperfusion decisions.
Does contemporary hemodynamic and perfusion-based risk stratification coupled with bleeding risk assessment optimize the selection of patients with acute pulmonary embolism for systemic thrombolysis or alternative reperfusion therapies?
Does contemporary hemodynamic and perfusion-based risk stratification coupled with bleeding risk assessment optimize the selection of patients with acute pulmonary embolism for systemic thrombolysis or alternative reperfusion therapies?
This narrative review synthesizes 2019 ESC and 2026 AHA/ACC guidelines to emphasize that systemic thrombolysis in acute pulmonary embolism should be guided by hemodynamic instability and end-organ hypoperfusion rather than anatomical clot burden, while carefully weighing competing bleeding risks and considering invasive reperfusion alternatives when fibrinolysis is contraindicated.
Answers are grounded in this paper and cite their sources.
Reserve systemic thrombolysis for unstable PE only; confirms guidelines while leaving open optimal catheter-directed strategies.
High-risk pulmonary embolism is a time-critical form of venous thromboembolism in which acute right ventricular failure can progress rapidly from compensated obstruction to shock and cardiac arrest. This narrative review examines how contemporary risk stratification should guide systemic thrombolysis and how bleeding risk modifies reperfusion decisions. A structured literature search conducted in 2026 used PubMed/MEDLINE together with current American Heart Association/American College of Cardiology, European Society of Cardiology, and CHEST guidance, prioritizing guidelines, randomized trials, meta-analyses, registries, and interventional consensus documents. The evidence supports defining high risk by cardiopulmonary consequences rather than clot location or radiological burden alone. Persistent hypotension, obstructive or cardiogenic shock, hypoperfusion, and cardiac arrest identify the groups most likely to require immediate reperfusion. Systemic thrombolysis remains a rapid and widely available option when life-threatening instability is present and bleeding risk is acceptable, whereas routine primary thrombolysis in normotensive patients is not supported because the reduction in hemodynamic deterioration is offset by major and intracranial bleeding. Patients with incipient failure require individualized escalation. When systemic fibrinolysis is contraindicated or unsuccessful, catheter-based therapy, mechanical throm bectomy, surgical embolectomy, and selected mechanical circulatory support should be considered without delaying definitive reperfusion.
No takes yet. Share an insight, caveat, or question.
Filho et al. (2026) conducted a review in Acute high-risk pulmonary embolism. Systemic thrombolysis (e.g., alteplase, tenecteplase) vs. Anticoagulation alone, catheter-directed therapy, mechanical thrombectomy, or surgical embolectomy was evaluated on Mortality, hemodynamic decompensation, recurrent pulmonary embolism, and major or intracranial bleeding. Systemic thrombolysis is recommended for acute PE with life-threatening hemodynamic instability and acceptable bleeding risk, but not routinely in normotensive patients due to bleeding hazards.
Synapse has enriched 10 related papers. Consider them for comparative context: